# Detection of germline variants in human population chronically exposed to high level natural background radiation in Kerala coast

**Authors:** Vinay Jain, Divyalakshmi Saini, Radhakrishnan Sabarinathan, Birajalaxmi Das

PMC · DOI: 10.1186/s41021-026-00352-4 · Genes and Environment · 2026-02-27

## TL;DR

This study examines genetic changes in people living in a high radiation area in Kerala and finds no significant differences in mutations, but notes unique variants possibly linked to DNA repair and epigenetic changes.

## Contribution

The study identifies unique SNVs and C > T transitions in a chronically irradiated population, suggesting potential epigenetic responses to low-dose radiation.

## Key findings

- No significant differences in SNVs or indels were found between high and normal radiation exposure groups.
- Unique SNVs in HLNRA individuals were overrepresented in DNA repair and epigenetic modification genes.
- C > T transitions in CpG regions were observed in HLNRA individuals, suggesting possible DNA methylation changes.

## Abstract

Genetic effects due to long term exposure to low doses of ionizing radiation (LDIR) in humans are not well understood. Human population living in high level natural radiation areas (HLNRAs) of Kerala coast in India are continuously exposed to chronic LDIR emanating from monazite containing beach sand for many generations. The background radiation level in this area varies from < 1.0 to 45mGy/year. The people residing in HLNRAs sometimes receives background radiation dose which is approximately 10–40 times higher than the people living in adjacent normal level natural radiation areas (NLNRAs). This population provides a unique opportunity to identify, if present, a mutational signature due to chronic low-dose radiation exposure in humans. We have employed whole exome sequencing approach to determine germline mutational changes in the lymphocytes of healthy individuals from HLNRAs (mean background dose: 31.8 ± 5.4 mGy/year, mean age: 43.0 ± 5.9 years) and compared them with healthy individuals from NLNRAs (mean background dose: 0.9 ± 0.2 mGy/year, mean age: 43.0 ± 11.3 years).

Our results revealed that the overall number of single nucleotide variants (SNVs) and insertions/deletions (indels) were not significantly different in HLNRA (7744 SNVs, 880 indels) and NLNRA (7951 SNVs, 856 indels) groups. A similar number of protein affecting mutations (PAMs) were observed in HLNRA (1925) and NLNRA (2082) individuals. Interestingly, several unique SNVs were identified in both the groups. In HLNRA, unique SNVs were overrepresented in genes involved in important biological pathways such as DNA repair (EXO1, PARP2, DDB1, POLQ, LIG1), epigenetic modification (KDM5D, SETDB2, KMT2B, BRD8, SIRT1), cell cycle progression (CDK14, CCND1) etc. Furthermore, significant predominance of C > T transitions which were unique to HLNRA group was observed preferentially at CpG dinucleotide regions. Analysis with REVEL and AloFT tools did not show any increase in potentially pathogenic mutations including those involved in carcinogenesis in HLNRA individuals exposed to chronic radiation.

This study did not show any significant changes in genetic variants due to long term exposure to LDIR in human population living in HLNRAs of Kerala coast. However, presence of unique SNVs and C > T transitions in CpG islands of HLNRA individuals indicate the possible role of epigenetic mechanisms i.e. DNA methylation in response to chronic LDIR in this population. This study significantly enhances the current understanding of radiation induced genetic changes and associated cancer risk in human population.

The online version contains supplementary material available at 10.1186/s41021-026-00352-4.

## Linked entities

- **Genes:** EXO1 (exonuclease 1) [NCBI Gene 9156], PARP2 (poly(ADP-ribose) polymerase 2) [NCBI Gene 10038], DDB1 (damage specific DNA binding protein 1) [NCBI Gene 1642], POLQ (DNA polymerase theta) [NCBI Gene 10721], LIG1 (DNA ligase 1) [NCBI Gene 3978], KDM5D (lysine demethylase 5D) [NCBI Gene 8284], SETDB2 (SET domain bifurcated histone lysine methyltransferase 2) [NCBI Gene 83852], KMT2B (lysine methyltransferase 2B) [NCBI Gene 9757], BRD8 (bromodomain containing 8) [NCBI Gene 10902], SIRT1 (sirtuin 1) [NCBI Gene 23411], CDK14 (cyclin dependent kinase 14) [NCBI Gene 5218], CCND1 (cyclin D1) [NCBI Gene 595]

## Full-text entities

- **Genes:** CBX4 (chromobox 4) [NCBI Gene 8535] {aka NBP16, PC2}, LIG1 [NCBI Gene 101093313], RAD23B (RAD23 nucleotide excision repair protein B) [NCBI Gene 5887] {aka HHR23B, HR23B, P58}, HSPA12B (heat shock protein family A (Hsp70) member 12B) [NCBI Gene 116835] {aka C20orf60}, JPH1 (junctophilin 1) [NCBI Gene 56704] {aka CMT2K, CMYO25, JP-1, JP1}, FANCA (FA complementation group A) [NCBI Gene 2175] {aka FA, FA-H, FA1, FAA, FACA, FAH}, SETDB2 (SET domain bifurcated histone lysine methyltransferase 2) [NCBI Gene 83852] {aka C13orf4, CLLD8, CLLL8, KMT1F}, PARP2 (poly(ADP-ribose) polymerase 2) [NCBI Gene 10038] {aka ADPRT2, ADPRTL2, ADPRTL3, ARTD2, PARP-2, pADPRT-2}, FANCL (FA complementation group L) [NCBI Gene 55120] {aka FAAP43, PHF9, POG}, CDK14 (cyclin dependent kinase 14) [NCBI Gene 5218] {aka PFTAIRE1, PFTK1}, XRCC3 [NCBI Gene 102901693], XRCC1 (X-ray repair cross complementing 1) [NCBI Gene 7515] {aka RCC, SCAR26}, USP39 [NCBI Gene 101086897], PAX8 (paired box 8) [NCBI Gene 7849] {aka PAX-8}, WNK1 (WNK lysine deficient protein kinase 1) [NCBI Gene 65125] {aka HSAN2, HSN2, KDP, PPP1R167, PRKWNK1, PSK}, BLK (BLK proto-oncogene, Src family tyrosine kinase) [NCBI Gene 640] {aka MODY11}, CD44 [NCBI Gene 101098744], NEIL1 (nei like DNA glycosylase 1) [NCBI Gene 79661] {aka FPG1, NEI1, hFPG1}, NBN (nibrin) [NCBI Gene 4683] {aka AT-V1, AT-V2, ATV, NBS, NBS1, P95}, CLDN10 [NCBI Gene 101096533], RECQL4 (RecQ like helicase 4) [NCBI Gene 9401] {aka RECQ4}, FYCO1 (FYVE and coiled-coil domain autophagy adaptor 1) [NCBI Gene 79443] {aka CATC2, CTRCT18, RUFY3, ZFYVE7}, RRBP1 (ribosome binding protein 1) [NCBI Gene 6238] {aka ES/130, ES130, RRp, hES, p180}, CDH1 [NCBI Gene 101095391], HERC2 (HECT and RLD domain containing E3 ubiquitin protein ligase 2) [NCBI Gene 8924] {aka D15F37S1, MRT38, SHEP1, jdf2, p528}, H2AX (H2A.X variant histone) [NCBI Gene 3014] {aka H2A.X, H2A/X, H2AFX}, HLA-DRB5 (major histocompatibility complex, class II, DR beta 5) [NCBI Gene 3127] {aka DRB5, HLA-DRB5*}, KMT2B [NCBI Gene 101098760], EPHB6 (EPH receptor B6) [NCBI Gene 2051] {aka HEP}, SNRNP35 [NCBI Gene 101101088], POLR3H (RNA polymerase III subunit H) [NCBI Gene 171568] {aka C25, RPC22.9, RPC8}, SMAD6 (SMAD family member 6) [NCBI Gene 4091] {aka AOVD2, HsT17432, MADH6, MADH7}, RABEPK (Rab9 effector protein with kelch motifs) [NCBI Gene 10244] {aka RAB9P40, bA65N13.1, p40}, TP53BP1 (tumor protein p53 binding protein 1) [NCBI Gene 7158] {aka 53BP1, TDRD30, p202, p53BP1}, PRSS1 (serine protease 1) [NCBI Gene 5644] {aka TRP1, TRY1, TRY4, TRYP1}, EP400 [NCBI Gene 101098167], FAN1 [NCBI Gene 101085979], RSL1D1 (ribosomal L1 domain containing 1) [NCBI Gene 26156] {aka CSIG, Cic1, L12, PBK1, UTP30}, ATP2C2 (ATPase secretory pathway Ca2+ transporting 2) [NCBI Gene 9914] {aka SPCA2}, SMARCC1 [NCBI Gene 101098204], GIGYF2 (GRB10 interacting GYF protein 2) [NCBI Gene 26058] {aka GYF2, PARK11, PERQ2, PERQ3, TNRC15}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, IFI27 (interferon alpha inducible protein 27) [NCBI Gene 3429] {aka FAM14D, ISG12, ISG12A, P27}, MRE11 [NCBI Gene 101086923], DIS3L2 (DIS3 like 3'-5' exoribonuclease 2) [NCBI Gene 129563] {aka FAM6A, PRLMNS, hDIS3L2}, FANCM [NCBI Gene 101086570], ZFHX3 (zinc finger homeobox 3) [NCBI Gene 463] {aka ATBF1, ATBT, ATFB8, C16orf47, EIG20, SCA4}, PABPC3 (poly(A) binding protein cytoplasmic 3) [NCBI Gene 5042] {aka PABP3, PABPL3, tPABP}, AXIN2 (axin 2) [NCBI Gene 8313] {aka AXIL, ODCRCS}, JPH3 (junctophilin 3) [NCBI Gene 57338] {aka CAGL237, HDL2, JP-3, JP3, TNRC22}, PARP2 [NCBI Gene 101090944], LIG1 (DNA ligase 1) [NCBI Gene 3978] {aka IMD96, LIGI, hLig1}, CCDC7 (coiled-coil domain containing 7) [NCBI Gene 79741] {aka BIOT2, BioT2-A, BioT2-B, BioT2-C, C10orf68}, BCL6 [NCBI Gene 101096665], POLQ (DNA polymerase theta) [NCBI Gene 10721] {aka PRO0327}, SMYD2 [NCBI Gene 101081435], EXO1 (exonuclease 1) [NCBI Gene 9156] {aka HEX1, hExoI}, NECTIN1 [NCBI Gene 101098252], SIRT1 [NCBI Gene 101087610], BRD3 (bromodomain containing 3) [NCBI Gene 8019] {aka FSHRG2, ORFX, RING3L}
- **Diseases:** birth defects (MESH:D000014), LDIR (MESH:D009800), A-bomb (MESH:D000075067), NLNRA (MESH:D011832), congenital malformations (OMIM:163000), hereditary anomalies (MESH:D009386), cancer (MESH:D009369), carcinogenesis (MESH:D063646), genetic diseases (MESH:D030342)
- **Chemicals:** HLNRAs (-), Uranium (MESH:D014501), Thorium (MESH:D013910), alcohol (MESH:D000438), EDTA (MESH:D004492), uracil (MESH:D014498), cytosine (MESH:D003596)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** I571T, T > A, M403I, T > C, R403Q, C > T, G761V, I125F, C > A, S279F, R525H, R152Q, R97W, R39Q, C1616Y, T > G, G160R, R317C, E270G, P305H, Y97C, A981T, G812R, C > G

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12958757/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12958757/full.md

## References

5 references — full list in the complete paper: https://tomesphere.com/paper/PMC12958757/full.md

---
Source: https://tomesphere.com/paper/PMC12958757